// App-Quantinova.ai

8044.0 : Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin’s.

Researchers

Presenter

  • Dietger Niederwieser

Principal Investigators

  • Caroline M. Hamm

  • Patrick Cobb

  • Mindy Mo

  • Cecily Forsyth

  • Alessandra Tucci

  • Vladimir Hanes

  • Vincent Delwail

  • Roman Hajek

  • David Chien

Medical Centers

  • University of Leipzig, Leipzig, Germany

  • Schulich School of Medicine and Dentistry, London, ON, Canada

  • SCL Health - St Vincent Frontier, Billings, MT

  • Amgen Inc, Thousand Oaks, CA

  • Gosford Hospital, New South Wales, Australia

  • Azienda AO Spedali Civili di Brescia, Brescia, Italy

  • ANOCEF Group, Centre Hospitalier Universitaire Poitiers, Poitiers, France

  • Department of Haematooncology, University Hospital Ostrava and the Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

Locations

  • Germany

  • Canada

  • United States

  • Australia

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • Sex hormone binding globulin

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved